Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.
Rolfo, C., Bronte, G., Sortino, G., Papadimitriou, K., Passiglia, F., Fiorentino, E., et al. (2014). The role of targeted therapy for gastrointestinal tumors. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 8(8), 875-885 [10.1586/17474124.2014.922870].
The role of targeted therapy for gastrointestinal tumors
BRONTE, Giuseppe;SORTINO, Giovanni;Papadimitriou, Konstantinos;PASSIGLIA, Francesco;FIORENTINO, Eugenio;RUSSO, Antonio;
2014-01-01
Abstract
Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.
| File | Dimensione | Formato | |
|---|---|---|---|
|
The role of targeted therapy.pdf
accesso aperto
Dimensione
329.22 kB
Formato
Adobe PDF
|
329.22 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
